Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by Spectral's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively in more than 80,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada. More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI. For further information please visit www.spectraldx.com

Paul Walker, M.D., Ph.D., F.R.C.S.C - President & Chief Executive Officer

Tony Businskas, B.A., C.A. - Executive Vice President & Chief Financial Officer

Debra M. Foster RN, B.Sc. (Human Biology) - Vice President, Clinical Development

Robert Verhagen B.Sc., MBA - Vice President, Business Development

R. Ian Lennox - Chairman of the Board

Paul Walker - Director

Anthony Bihl - Director

Kevin Giese - Director

Guillermo Herrera - Director

Edward E. McCormack - Director

Laine Woollard - Director